A Multicentre, Randomised Trial to Compare the Effect of Two Blinded Doses of CASODEX (AstraZeneca 176,334; 100 mg and 150 mg po daily) and Castration in the Treatment of Advanced Carcinoma of the Prostate
Study identifier:176334-0306
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Multicentre, Randomised Trial to Compare the Effect of Two Blinded Doses of CASODEX (AstraZeneca 176,334; 100 mg and 150 mg po daily) and Castration in the Treatment of Advanced Carcinoma of the Prostate
Medical condition
prostate cancer
Phase
Phase 3
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
